Keyword: David Ricks

Jockeying for market share, Eli Lilly offered more than half off its U.S. list prices in the form of rebates and discounts last year.

Former Eli Lilly CFO Derica Rice becomes the second top Big Pharma ex to take the reins at a major pharmacy benefit manager.

Despite sliding share prices and an ill-fated tribal licensing deal, CEO Brent Saunders nabbed compensation eight times higher than his 2016 pay.

UnitedHealthcare is planning to offer rebates directly back to millions of patients—a move that addresses a top criticism from the drug industry.

After Lilly CEO David Ricks took over in 2016, he revamped management while cutting costs and jobs—and earned nearly $16 million in pay for his efforts.

Does industry still fear the threat of pricing reform from the Trump Administration?

As the drug industry took heat in 2017 for "getting away with murder," among other criticisms, its lobbyists were busy behind the scenes.

Payer discounts are likely to grow even if midterm elections revive attacks on the industry—and investors should be worried about that, analysts say.

Merck & Co.'s top executive said Monday that pricing pressure isn't likely to get worse. But Eli Lilly CEO David Ricks begs to differ.

The 2018 J.P. Morgan Healthcare Conference is receding in biopharma's rearview mirror, but industry watchers have only begun digesting the commentary.